Combination of Anti-programmed Cell Death Protein 1 and Antiangiogenesis Displaying a Response Disparity between Pulmonary and Nonpulmonary Metastases
Targeting the vascular endothelial growth factor-mediated immune suppression is a strategy to overcome the resistance of anti-programmed cell death protein 1/programmed death-ligand 1 (anti-PD-1/PD-L1) therapy. Here, we present two cases, including one case with leiomyosarcoma and the other one with...
Saved in:
Main Authors: | Bing-Syuan Chung, Peng-Chan Lin, Shang-Hung Chen, Yu-Min Yeh |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2023-10-01
|
Series: | Journal of Cancer Research and Practice |
Subjects: | |
Online Access: | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00016 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Leiomyosarcoma in a dos
by: Zabid Yener, et al. -
Alleviating Tumor Hypoxia and Immunosuppression via Sononeoperfusion: A New Ally for potentiating anti-PD-L1 blockade of solid Tumor
by: Guoliang Yang, et al.
Published: (2025-01-01) -
The role of ferroptosis in colorectal cancer and its potential synergy with immunotherapy
by: Wenhua Xia, et al.
Published: (2025-01-01) -
Primary bronchial leiomyosarcoma: a diagnostic challenge
by: Dan Chen, et al.
Published: (2025-01-01) -
Primary leiomyosarcoma of the scalp: a case report and review of the literature
by: Shuo Gao, et al.
Published: (2025-02-01)